首页>投融资
Noema Pharma
B轮
Noema Pharma is a biotech company developing therapies to address the most disabling symptoms in orphan conditions of the brain and nervous system. Noema’s research and development is focused on understanding and meeting patient needs using our novel therapies.In March 2023, SOFINNOVA PARTNERS SAS announced that Noema Pharma AG raised an oversubscribed CHF 103 million series B financing round. Later that month, Noema Pharma announced that it had successfully completed a Series B financing round and subsequently raised $112m from new and existing investors.In March 2023, Noema Pharma AG closed an oversubscribed Series B financing round raising CHF 103 million.In December 2020, Noema Pharma had successfully concluded an oversubscribed Series A financing round, raising CHF54 million ($59 million USD) to fund further development of its promising clinical-stage pipeline
基本信息
-
公司全称Noema Pharma AG
-
类型神经系统疾病治疗药物开发商
-
产业领域医药研发/制造、化学&生物药
-
公司人数15人以下
-
地址Barfuesserplatz 3 BASEL BASEL-STADT 4051; CH;
-
联系电话+41 58 211 34 0
-
邮箱info@noemapharma.com
-
成立时间2019-01-01
投融资
-
2024-12-11B轮2700万瑞士法郎EQT PartnersLSP 7Forbion Capital PartnersJeito CapitalSofinnova PartnersGilde HealthcarePolaris PartnersInvusUPMC Enterprise
-
2023-03-07B轮1.12亿美元Forbion Capital PartnersSofinnova PartnersJeito CapitalUPMC EnterprisesGilde HealthcareInvusPolaris Partners
-
2023-03-07B轮1.12亿美元InvusPolaris PartnersGilde HealthcareJeito CapitalSofinnova PartnersForbion Capital PartnersUPMC Enterprise
-
2020-12-01A轮5400万瑞士法郎Sofinnova PartnersPolaris Partners
-
2020-12-01A轮5400万瑞士法郎Sofinnova PartnersPolaris Partners
- 加载更多
相关投融资企业
A轮
Ouro Medicines是一家免疫重置公司，通过结合科学专业知识、通过临床推进细胞耗竭疗法的跟踪记录以及强大的管道来正面应对慢性免疫介导的疾病。Ouro最领先的候选产品是OM336，这是一种最近从康诺亚生物获得许可的BCMA靶向的双特异性TCE。
A轮
RhyGaze开发一种新的基因疗法，旨在恢复患者的视力。该公司的治疗技术将光传感器基因专门传递给失去光敏感性的视锥细胞，并修复其检测光的能力，使医疗保健行业能够为失明患者提供视力恢复。
未公开
Thetis Pharmaceuticals LLC is a pharmaceutical company focused on the development of prescription drugs for diabetes, hypertriglyceridemia and dyslipidemia. Thetis's proprietary HEALER technology (High Efficiency Amino Lipid Enabled Release) uses transformative ionic chemistry to revitalize proven therapeutic agents and generated solid, stable APIs.In July 2021, Thetis Pharmaceuticals LLC announced the launch of a new program in cancer TP-317, which is a Resolvin E1 therapy for the treatment of solid tumour cancers published in the Journal of Experimental Medicine.In May 2013, the company raised $5.7 million through a series A financing.In September 2011, Thetis secured first round funding. At that time, the company planned to secure additional capital in the second half of 2012
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息